TILRAY BRANDS INC (TLRY.CA) Stock Fundamental Analysis
Canada - TSX:TLRY - US88688T1007 - Common Stock
2.38 CAD
+0.15 (+6.73%)
Taking everything into account, TLRY scores 2 out of 10 in our fundamental rating. TLRY was compared to 32 industry peers in the Pharmaceuticals industry. TLRY may be in some trouble as it scores bad on both profitability and health. TLRY is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TLRY has reported negative net income.
In the past year TLRY has reported a negative cash flow from operations.
TLRY had negative earnings in each of the past 5 years.
In the past 5 years TLRY reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -105.42%, TLRY is doing worse than 84.38% of the companies in the same industry.
TLRY has a Return On Equity of -144.68%. This is in the lower half of the industry: TLRY underperforms 78.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -105.42% | ||
| ROE | -144.68% | ||
| ROIC | N/A |
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 29.29%, TLRY is in line with its industry, outperforming 46.88% of the companies in the same industry.
In the last couple of years the Gross Margin of TLRY has grown nicely.
TLRY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.29% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TLRY has been increased compared to 1 year ago.
The number of shares outstanding for TLRY has been increased compared to 5 years ago.
The debt/assets ratio for TLRY is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -0.81, we must say that TLRY is in the distress zone and has some risk of bankruptcy.
TLRY's Altman-Z score of -0.81 is in line compared to the rest of the industry. TLRY outperforms 50.00% of its industry peers.
TLRY has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.19, TLRY perfoms like the industry average, outperforming 59.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.81 |
ROIC/WACCN/A
WACC7.84%
2.3 Liquidity
TLRY has a Current Ratio of 2.46. This indicates that TLRY is financially healthy and has no problem in meeting its short term obligations.
TLRY's Current ratio of 2.46 is in line compared to the rest of the industry. TLRY outperforms 59.38% of its industry peers.
A Quick Ratio of 1.49 indicates that TLRY should not have too much problems paying its short term obligations.
TLRY's Quick ratio of 1.49 is fine compared to the rest of the industry. TLRY outperforms 62.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.46 | ||
| Quick Ratio | 1.49 |
3. Growth
3.1 Past
TLRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -648.00%.
TLRY shows a small growth in Revenue. In the last year, the Revenue has grown by 4.10%.
TLRY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.52% yearly.
EPS 1Y (TTM)-648%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)4.1%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%
3.2 Future
TLRY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.55% yearly.
TLRY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.43% yearly.
EPS Next Y92.83%
EPS Next 2Y39.35%
EPS Next 3Y26.96%
EPS Next 5Y15.55%
Revenue Next Year3.05%
Revenue Next 2Y3.9%
Revenue Next 3Y4.1%
Revenue Next 5Y4.43%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TLRY. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLRY. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as TLRY.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 73.4 |
4.3 Compensation for Growth
A more expensive valuation may be justified as TLRY's earnings are expected to grow with 26.96% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.35%
EPS Next 3Y26.96%
5. Dividend
5.1 Amount
No dividends for TLRY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:TLRY (10/15/2025, 7:00:00 PM)
2.38
+0.15 (+6.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners9.86%
Inst Owner ChangeN/A
Ins Owners0.36%
Ins Owner ChangeN/A
Market Cap2.64B
Analysts72.5
Price Target1.45 (-39.08%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-2749.13%
Min EPS beat(2)-5362.97%
Max EPS beat(2)-135.29%
EPS beat(4)0
Avg EPS beat(4)-1413.07%
Min EPS beat(4)-5362.97%
Max EPS beat(4)-8.93%
EPS beat(8)1
Avg EPS beat(8)-730.51%
EPS beat(12)1
Avg EPS beat(12)-762.79%
EPS beat(16)3
Avg EPS beat(16)-613.4%
Revenue beat(2)0
Avg Revenue beat(2)-10.25%
Min Revenue beat(2)-13.28%
Max Revenue beat(2)-7.23%
Revenue beat(4)0
Avg Revenue beat(4)-8.93%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)-4.66%
Revenue beat(8)0
Avg Revenue beat(8)-5.77%
Revenue beat(12)1
Avg Revenue beat(12)-3.93%
Revenue beat(16)1
Avg Revenue beat(16)-4.24%
PT rev (1m)6.8%
PT rev (3m)-19.66%
EPS NQ rev (1m)0%
EPS NQ rev (3m)59.09%
EPS NY rev (1m)1.82%
EPS NY rev (3m)41.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.19%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.29 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.24 | ||
| P/tB | 2.55 | ||
| EV/EBITDA | 73.4 |
EPS(TTM)-2.1
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS1.04
BVpS1.91
TBVpS0.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -105.42% | ||
| ROE | -144.68% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 29.29% | ||
| FCFM | N/A |
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
F-Score4
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.19 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 11.15 | ||
| Cap/Depr | 24.66% | ||
| Cap/Sales | 4.01% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.46 | ||
| Quick Ratio | 1.49 | ||
| Altman-Z | -0.81 |
F-Score4
WACC7.84%
ROIC/WACCN/A
Cap/Depr(3y)21.23%
Cap/Depr(5y)65.01%
Cap/Sales(3y)3.68%
Cap/Sales(5y)7.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-648%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y92.83%
EPS Next 2Y39.35%
EPS Next 3Y26.96%
EPS Next 5Y15.55%
Revenue 1Y (TTM)4.1%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%
Revenue Next Year3.05%
Revenue Next 2Y3.9%
Revenue Next 3Y4.1%
Revenue Next 5Y4.43%
EBIT growth 1Y-11.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.7%
EBIT Next 3Y29.62%
EBIT Next 5Y17.51%
FCF growth 1Y-111.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-206.1%
OCF growth 3YN/A
OCF growth 5YN/A